[go: up one dir, main page]

MX2023007524A - Composiciones y metodos para edicion epigenetica. - Google Patents

Composiciones y metodos para edicion epigenetica.

Info

Publication number
MX2023007524A
MX2023007524A MX2023007524A MX2023007524A MX2023007524A MX 2023007524 A MX2023007524 A MX 2023007524A MX 2023007524 A MX2023007524 A MX 2023007524A MX 2023007524 A MX2023007524 A MX 2023007524A MX 2023007524 A MX2023007524 A MX 2023007524A
Authority
MX
Mexico
Prior art keywords
compositions
methods
epigenetic
epigenetic editing
editing
Prior art date
Application number
MX2023007524A
Other languages
English (en)
Inventor
Morgan Maeder
Ari Friedland
Samantha Linder
Vic Myer
Original Assignee
Chroma Medicine Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chroma Medicine Inc filed Critical Chroma Medicine Inc
Publication of MX2023007524A publication Critical patent/MX2023007524A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/1003—Transferases (2.) transferring one-carbon groups (2.1)
    • C12N9/1007—Methyltransferases (general) (2.1.1.)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/22—Ribonucleases [RNase]; Deoxyribonucleases [DNase]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y201/00—Transferases transferring one-carbon groups (2.1)
    • C12Y201/01—Methyltransferases (2.1.1)
    • C12Y201/01037—DNA (cytosine-5-)-methyltransferase (2.1.1.37)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/80—Fusion polypeptide containing a DNA binding domain, e.g. Lacl or Tet-repressor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/80—Fusion polypeptide containing a DNA binding domain, e.g. Lacl or Tet-repressor
    • C07K2319/81—Fusion polypeptide containing a DNA binding domain, e.g. Lacl or Tet-repressor containing a Zn-finger domain for DNA binding
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPR]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/80—Vectors containing sites for inducing double-stranded breaks, e.g. meganuclease restriction sites

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

En la presente se divulgan composiciones y métodos que comprenden editores epigenéticos para edición epigenética o células, ácidos nucleicos y vectores que comprenden los mismos. También se divulgan cromosomas epigenéticamente modificados.
MX2023007524A 2020-12-22 2021-12-22 Composiciones y metodos para edicion epigenetica. MX2023007524A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063129283P 2020-12-22 2020-12-22
US202163280452P 2021-11-17 2021-11-17
PCT/US2021/064913 WO2022140577A2 (en) 2020-12-22 2021-12-22 Compositions and methods for epigenetic editing

Publications (1)

Publication Number Publication Date
MX2023007524A true MX2023007524A (es) 2023-09-19

Family

ID=82160095

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023007524A MX2023007524A (es) 2020-12-22 2021-12-22 Composiciones y metodos para edicion epigenetica.

Country Status (10)

Country Link
US (1) US20240076678A1 (es)
EP (1) EP4267743A4 (es)
JP (1) JP2024501383A (es)
KR (1) KR20240011120A (es)
AU (1) AU2021409729A1 (es)
CA (1) CA3202977A1 (es)
GB (1) GB2619423A (es)
IL (1) IL303923A (es)
MX (1) MX2023007524A (es)
WO (1) WO2022140577A2 (es)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN119095972B (zh) * 2022-03-04 2025-11-28 益杰立科新加坡有限公司 基因组编辑的组合物和方法
CN119836432A (zh) * 2022-05-01 2025-04-15 恩科洛玛生物公司 用于pcsk9表达的表观遗传调节的组合物和方法
AU2023289696A1 (en) 2022-06-24 2025-01-16 Tune Therapeutics, Inc. Compositions, systems, and methods for reducing low-density lipoprotein through targeted gene repression
CA3261865A1 (en) * 2022-07-12 2024-01-18 Tune Therapeutics, Inc. TARGETED TRANSCRIPTIONAL ACTIVATION COMPOSITIONS, SYSTEMS AND METHODS
KR20250077608A (ko) 2022-08-19 2025-05-30 튠 쎄라퓨틱스, 인코포레이티드 표적 유전자 억제를 통한 b형 간염 바이러스 조절용 조성물, 시스템 및 방법
WO2024044572A1 (en) * 2022-08-23 2024-02-29 The Regents Of The University Of California Modified dna binding proteins and methods of use thereof
WO2024044574A1 (en) * 2022-08-23 2024-02-29 The Regents Of The University Of California Compositions and methods for reducing ionizing radiation-induced hematopoietic stem cell damage
CA3268237A1 (en) * 2022-09-23 2024-03-28 Nchroma Bio, Inc. COMPOSITIONS AND METHODS FOR THE EPIGENETIC REGULATION OF HBV GENE EXPRESSION
WO2024081879A1 (en) * 2022-10-14 2024-04-18 Chroma Medicine, Inc. Compositions and methods for epigenetic regulation of cd247 expression
CN120476211A (zh) * 2022-12-23 2025-08-12 益杰立科新加坡有限公司 融合物及其用途
WO2024131917A1 (zh) * 2022-12-23 2024-06-27 益杰立科(上海)生物科技有限公司 复合物及其用途
WO2024145615A2 (en) * 2022-12-30 2024-07-04 Chroma Medicine, Inc. Compositions and methods for epigenetic regulation of angptl3 expression
WO2024158777A1 (en) * 2023-01-23 2024-08-02 The General Hospital Corporation Methods and compositions for inhibiting suppression of anti-tumor immunity by targeting ligand-receptor interactions present in the placenta
US12252715B2 (en) 2023-02-17 2025-03-18 Whitehead Institute For Biomedical Research Compositions and methods for making epigenetic modifications
WO2024178402A2 (en) * 2023-02-24 2024-08-29 Chroma Medicine, Inc. Compositions and methods for epigenetic regulation of complement factor expression
WO2024178628A1 (en) * 2023-02-28 2024-09-06 Sun Yat-Sen University Epigenetic editor assisted by phase separation proteins
AU2024230979A1 (en) * 2023-03-06 2025-10-16 Nchroma Bio, Inc. Compositions and methods for epigenetic regulation of pcsk9 expression
WO2024206565A1 (en) * 2023-03-29 2024-10-03 Scribe Therapeutics Inc. Repressor fusion protein systems
WO2024220857A1 (en) * 2023-04-20 2024-10-24 Chroma Medicine, Inc. Fusion proteins for epigenetic regulation
WO2024229018A2 (en) * 2023-05-01 2024-11-07 The University Of Chicago Engineered compact crispr-cas12f system
WO2024238700A1 (en) * 2023-05-15 2024-11-21 Chroma Medicine, Inc. Compositions and methods for epigenetic regulation of hbv gene expression
AU2024270764A1 (en) 2023-05-15 2025-12-04 Nchroma Bio, Inc. Compositions and methods for epigenetic regulation of hbv gene expression
WO2025019807A2 (en) * 2023-07-19 2025-01-23 Chroma Medicine, Inc. Compositions and methods for epigenetic regulation of rfxap expression
WO2025030130A1 (en) * 2023-08-03 2025-02-06 Chroma Medicine, Inc. Methods and compositions comprising dnmt3a-binding antibodies
WO2025049303A1 (en) * 2023-08-25 2025-03-06 Nchroma Bio, Inc. Compositions and methods for epigenetic regulation
WO2025049789A1 (en) * 2023-09-01 2025-03-06 Chroma Medicine, Inc. Compositions and methods for epigenetic regulation of adora2a expression
WO2025101722A1 (en) * 2023-11-07 2025-05-15 Axoiya Inc. High-affinity engineered chromodomains
WO2025102001A1 (en) * 2023-11-10 2025-05-15 Nchroma Bio, Inc. Compositions and methods for multiplex epigenetic regulation
WO2025106523A1 (en) * 2023-11-14 2025-05-22 Nchroma Bio, Inc. Compositions and methods for epigenetic regulation of f8 expression
WO2025117544A1 (en) 2023-11-29 2025-06-05 The Broad Institute, Inc. Engineered omega guide molecule and iscb compositions, systems, and methods of use thereof
WO2025160155A1 (en) * 2024-01-22 2025-07-31 The Broad Institute, Inc. Epigenetic targeting of prion diseases
WO2025166202A1 (en) 2024-01-31 2025-08-07 Modernatx, Inc. Lipid nanoparticle compositions comprising sialic acid derivatives and the uses thereof
WO2025264819A1 (en) * 2024-06-18 2025-12-26 Nchroma Bio, Inc. Compositions and methods for epigenetic regulation of znf410 expression
WO2025261475A1 (zh) * 2024-06-21 2025-12-26 益杰立科(上海)生物科技有限公司 靶向血管内皮生长因子的工程化基因转录阻抑工具及用途

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6534261B1 (en) 1999-01-12 2003-03-18 Sangamo Biosciences, Inc. Regulation of endogenous gene expression in cells using zinc finger proteins
US6453242B1 (en) 1999-01-12 2002-09-17 Sangamo Biosciences, Inc. Selection of sites for targeting by zinc finger proteins and methods of designing zinc finger proteins to bind to preselected sites
CA3073384A1 (en) 2008-09-05 2010-03-11 President And Fellows Of Harvard College Continuous directed evolution of proteins and nucleic acids
LT2566972T (lt) 2010-05-03 2020-03-10 Sangamo Therapeutics, Inc. Kompozicijos, skirtos cinko pirštu modulių susiejimui
US9340799B2 (en) 2013-09-06 2016-05-17 President And Fellows Of Harvard College MRNA-sensing switchable gRNAs
US9737604B2 (en) 2013-09-06 2017-08-22 President And Fellows Of Harvard College Use of cationic lipids to deliver CAS9
WO2016011070A2 (en) 2014-07-14 2016-01-21 The Regents Of The University Of California A protein tagging system for in vivo single molecule imaging and control of gene transcription
GB201418965D0 (es) * 2014-10-24 2014-12-10 Ospedale San Raffaele And Fond Telethon
US10676726B2 (en) * 2015-02-09 2020-06-09 Duke University Compositions and methods for epigenome editing
EP3382018B1 (en) 2015-11-25 2022-03-30 National University Corporation Gunma University Dna methylation editing kit and dna methylation editing method
JP7308143B2 (ja) * 2016-08-19 2023-07-13 ホワイトヘッド・インスティテュート・フォー・バイオメディカル・リサーチ Ｄｎａメチル化の編集方法
WO2018049075A1 (en) * 2016-09-07 2018-03-15 Flagship Pioneering, Inc. Methods and compositions for modulating gene expression
CA3038960A1 (en) 2016-09-30 2018-04-05 The Regents Of The University Of California Rna-guided nucleic acid modifying enzymes and methods of use thereof
BR112019006388A2 (pt) 2016-09-30 2019-06-25 Univ California enzimas modificadoras de ácido nucleico guiadas por rna e métodos de uso das mesmas
WO2018089664A1 (en) 2016-11-11 2018-05-17 The Regents Of The University Of California Variant rna-guided polypeptides and methods of use
BR112019021719A2 (pt) * 2017-04-21 2020-06-16 The General Hospital Corporation Variantes de cpf1 (cas12a) com especificidade para pam alterada
WO2019089804A1 (en) 2017-11-01 2019-05-09 The Regents Of The University Of California Casy compositions and methods of use
CN112334577B (zh) * 2018-04-19 2023-10-17 加利福尼亚大学董事会 用于基因编辑的组合物和方法
WO2019236566A1 (en) 2018-06-05 2019-12-12 Lifeedit, Inc. Rna-guided nucleases and active fragments and variants thereof and methods of use
US20210284981A1 (en) * 2018-07-24 2021-09-16 The Regents Of The University Of California Rna-guided nucleic acid modifying enzymes and methods of use thereof
EP3841205A4 (en) 2018-08-22 2022-08-17 The Regents of The University of California Variant type v crispr/cas effector polypeptides and methods of use thereof

Also Published As

Publication number Publication date
CA3202977A1 (en) 2022-06-30
EP4267743A2 (en) 2023-11-01
US20240076678A1 (en) 2024-03-07
AU2021409729A1 (en) 2023-07-13
KR20240011120A (ko) 2024-01-25
GB2619423A (en) 2023-12-06
WO2022140577A2 (en) 2022-06-30
GB202311318D0 (en) 2023-09-06
IL303923A (en) 2023-08-01
WO2022140577A3 (en) 2022-11-03
EP4267743A4 (en) 2024-12-18
JP2024501383A (ja) 2024-01-11

Similar Documents

Publication Publication Date Title
MX2023007524A (es) Composiciones y metodos para edicion epigenetica.
WO2021231691A8 (en) Methods and compositions for the adar-mediated editing of retinoschisin 1 (rs1)
MX2022011039A (es) Sistemas crispr clase ii tipo v.
EP4431607A3 (en) High-throughput precision genome editing
MX2025007036A (es) Metodos y composiciones para generar alelos dominantes usando edicion del genoma
WO2021055459A8 (en) Highly efficient dna base editors mediated by rna-aptamer recruitment for targeted genome modification and uses thereof
PH12021550904A1 (en) Novel crispr/cas12f enzyme and system
WO2019089884A3 (en) Methods, compositions and components for crispr-cas9 editing of tgfbr2 in t cells for immunotherapy
MX2025009289A (es) Inserciones de adn no virales orientadas
MX2022007575A (es) Anticuerpos anti cumulo de diferenciacion 73 (cd73) y usos de estos.
MX2018001617A (es) Composiciones de crispr-cas9 diseñados y metodos de uso.
WO2020081149A8 (en) Improved detection of nuclease edited sequences in automated modules and instruments
EP4321617A3 (en) Crispr/cpf1 systems and methods
WO2020003006A3 (en) Compositions and methods for genomic editing by insertion of donor polynucleotides
EP4317447A3 (en) Donor repair templates multiplex genome editing
MX2024002927A (es) Metodos y composiciones para modular un genoma.
EP4434589A3 (en) Evolved cas9 proteins for gene editing
MX2024002988A (es) Composiciones y metodos moduladores de la serpina.
WO2022051020A3 (en) Systems, methods, and compositions for rna-guided rna-targeting crispr effectors
WO2020198174A8 (en) Simultaneous multiplex genome editing in yeast
AU2021216418A8 (en) Compositions and methods for targeting, editing or modifying human genes
WO2020186059A3 (en) Novel high fidelity rna-programmable endonuclease systems and uses thereof
MX2025000138A (es) Composiciones y metodos para edicion epigenetica
MX2025001083A (es) Sistemas crispr de clase ii, tipo v
MX2025000052A (es) Composiciones y metodos para la regulacion epigenetica de la expresion de b2m